169 related articles for article (PubMed ID: 34615718)
1. Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.
Rottey S; Clarke J; Aung K; Machiels JP; Markman B; Heinhuis KM; Millward M; Lolkema M; Patel SP; de Souza P; Duca M; Curigliano G; Santoro A; Koyama T; Brown M; Vezina H; He C; Chu QS
Clin Cancer Res; 2022 Jan; 28(1):95-105. PubMed ID: 34615718
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
[TBL] [Abstract][Full Text] [Related]
3. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Gutierrez M; Moreno V; Heinhuis KM; Olszanski AJ; Spreafico A; Ong M; Chu Q; Carvajal RD; Trigo J; Ochoa de Olza M; Provencio M; De Vos FY; De Braud F; Leong S; Lathers D; Wang R; Ravindran P; Feng Y; Aanur P; Melero I
Clin Cancer Res; 2021 Jan; 27(2):460-472. PubMed ID: 33148673
[TBL] [Abstract][Full Text] [Related]
4. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Bagegni NA; Park H; Kraft K; O-Toole M; Gao F; Waqar SN; Ratner L; Morgensztern D; Devarakonda S; Amin M; Baggstrom MQ; Liang C; Selvaggi G; Wang-Gillam A
Cancer Chemother Pharmacol; 2022 Apr; 89(4):487-497. PubMed ID: 35247086
[TBL] [Abstract][Full Text] [Related]
5. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
7. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma.
Huynh JC; Cho M; Monjazeb A; Al-Obeidi E; Singh A; Tam K; Lara F; Martinez A; Garcia L; Kim EJ
Invest New Drugs; 2024 Feb; 42(1):35-43. PubMed ID: 38038862
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
[TBL] [Abstract][Full Text] [Related]
10. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
Ma Y; Fang W; Zhang Y; Yang Y; Hong S; Zhao Y; Tendolkar A; Chen L; Xu D; Sheng J; Zhao H; Zhang L
Oncologist; 2019 Jul; 24(7):891-e431. PubMed ID: 31048330
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors.
Wang R; Baxi V; Li Z; Locke D; Hedvat C; Sun Y; Walsh AM; Shao X; Basavanhally T; Greenawalt DM; Patah P; Novosiadly R
ESMO Open; 2023 Apr; 8(2):100784. PubMed ID: 36863094
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
[TBL] [Abstract][Full Text] [Related]
14. Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Hong DS; Postow M; Chmielowski B; Sullivan R; Patnaik A; Cohen EEW; Shapiro G; Steuer C; Gutierrez M; Yeckes-Rodin H; Ilaria R; O'Connell B; Peng J; Peng G; Zizlsperger N; Tolcher A; Wolchok JD
Clin Cancer Res; 2023 Jun; 29(12):2210-2219. PubMed ID: 37000164
[TBL] [Abstract][Full Text] [Related]
15. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; Ruth He A; El-Rayes BF; Acosta-Rivera M; Lim HY; Neely J; Shen Y; Wisniewski T; Anderson J; Hsu C
JAMA Oncol; 2020 Nov; 6(11):e204564. PubMed ID: 33001135
[TBL] [Abstract][Full Text] [Related]
17. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
18. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors.
Hollebecque A; Chung HC; de Miguel MJ; Italiano A; Machiels JP; Lin CC; Dhani NC; Peeters M; Moreno V; Su WC; Chow KH; Galvao VR; Carlsen M; Yu D; Szpurka AM; Zhao Y; Schmidt SL; Gandhi L; Xu X; Bang YJ
Clin Cancer Res; 2021 Dec; 27(23):6393-6404. PubMed ID: 34465599
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
20. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Gettinger SN; Horn L; Gandhi L; Spigel DR; Antonia SJ; Rizvi NA; Powderly JD; Heist RS; Carvajal RD; Jackman DM; Sequist LV; Smith DC; Leming P; Carbone DP; Pinder-Schenck MC; Topalian SL; Hodi FS; Sosman JA; Sznol M; McDermott DF; Pardoll DM; Sankar V; Ahlers CM; Salvati M; Wigginton JM; Hellmann MD; Kollia GD; Gupta AK; Brahmer JR
J Clin Oncol; 2015 Jun; 33(18):2004-12. PubMed ID: 25897158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
